Guggenheim Capital LLC Invests $643,000 in Haleon plc (NYSE:HLN)

Guggenheim Capital LLC acquired a new stake in shares of Haleon plc (NYSE:HLN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 67,358 shares of the company's stock, valued at approximately $643,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Sierra Ocean LLC bought a new stake in Haleon in the 4th quarter valued at $26,000. Versant Capital Management Inc boosted its position in shares of Haleon by 2,029.1% during the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company's stock valued at $34,000 after acquiring an additional 3,348 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in Haleon in the fourth quarter valued at about $35,000. FIL Ltd raised its position in Haleon by 45.7% in the fourth quarter. FIL Ltd now owns 4,049 shares of the company's stock worth $39,000 after purchasing an additional 1,270 shares in the last quarter. Finally, Spire Wealth Management acquired a new position in Haleon in the fourth quarter worth about $39,000. 6.67% of the stock is currently owned by institutional investors.

Haleon Price Performance

HLN traded up $0.05 during trading on Monday, hitting $10.23. The company's stock had a trading volume of 14,164,885 shares, compared to its average volume of 7,381,708. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $46.17 billion, a price-to-earnings ratio of 30.09, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24. The firm's 50 day moving average price is $10.14 and its two-hundred day moving average price is $9.80. Haleon plc has a 12 month low of $8.12 and a 12 month high of $10.80.

Haleon (NYSE:HLN - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The business had revenue of $3.54 billion during the quarter, compared to analysts' expectations of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. Sell-side analysts forecast that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The business also recently declared a -- dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be paid a dividend of $0.1166 per share. This is a boost from Haleon's previous -- dividend of $0.05. This represents a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, April 25th. Haleon's dividend payout ratio is 58.97%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Sanford C. Bernstein lowered Haleon from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 8th. HSBC reiterated a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Haleon in a report on Monday, March 3rd. Morgan Stanley downgraded shares of Haleon from an "overweight" rating to an "equal weight" rating in a research note on Friday, January 10th. Finally, Hsbc Global Res cut shares of Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Six research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.